Lung Cancer Dispatch
Follow
Find tag "nanoparticles"
4.4K views | +2 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Genprex Begins Phase II Clinical Trial for Lung Cancer

"Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways.


"The trial is significant in that it seeks to determine if patients without the EGFR activating mutation as well as patients with the EGFR activating mutation whose cancer has progressed after erlotinib treatment can benefit from the Oncoprex + erlotinib combination therapy. While erlotinib is a blockbuster drug helping many cancer patients worldwide, research shows that the vast majority of patients who have lung cancers without the activating EGFR mutation are unlikely to benefit from erlotinib. Additionally, many patients with the activating EGFR mutation who respond to erlotinib therapy eventually become resistant to the therapy."


Editor's note: Clinical trials are studies done with volunteer patients to evaluate the safety and effectiveness of new treatments (learn more in our lung cancer KnowledgeBase). This clinical trial is testing a new targeted therapy drug called Oncoprex. When combined with the drug erlotinib (Tarceva), Oncoprex may help treat patients who usually do not benefit from erlotinib or who have grown resistant to it.

Cancer Commons's insight:

Yahoo!  |  May 20, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

New Way to Find and Kill Cancer Cells

New Way to Find and Kill Cancer Cells | Lung Cancer Dispatch | Scoop.it

A tiny new particle could pack a powerful anticancer punch, promising to speed diagnosis and pinpoint drug delivery. Conventional nanoparticles can only carry cancer-fighting materials on their surfaces, limiting their effectiveness. In contrast, the new 'Janus' nanoparticle has a porous interior that lets it carry cancer tests and treatments at the same time. Other uses for the new particle include delivering fluorescent dyes to illuminate cancer cells, making them easier for surgeons to find. This technological advance was presented at the 2013 Materials Science & Technology Conference in Canada.

Cancer Commons's insight:

Science Daily│Oct 28, 2013

more...
Cancer Commons's curator insight, October 31, 2013 3:21 PM

Science Daily│Oct 28, 2013

Cancer Commons's curator insight, November 1, 2013 3:04 PM

Science Daily│Oct 28, 2013

Scooped by Cancer Commons
Scoop.it!

Chemotherapy Timing is Key to Success — Nanoparticles that Stagger Delivery of 2 Drugs Knock out Aggressive Tumors in Mice

Chemotherapy Timing is Key to Success — Nanoparticles that Stagger Delivery of 2 Drugs Knock out Aggressive Tumors in Mice | Lung Cancer Dispatch | Scoop.it

"MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage.


"In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast tumors. The MIT team, led by Michael Yaffe, the David H. Koch Professor in Science, and Paula Hammond, the David H. Koch Professor in Engineering, describe the findings in the online edition of Science Signaling."


Editor's note: This story is about a new treatment that has been studied in mice. While it is possible that the treatment could eventually make it to clinical trials with humans, the treatment currently cannot be used to treat cancer.

Cancer Commons's insight:

Bionity.com  |  May 12, 2014

more...
No comment yet.